Larimar Therapeutics, Inc. (LRMR)
3.83
-0.04
(-1.03%)
USD |
NASDAQ |
Sep 03, 10:04
Larimar Therapeutics Debt to Equity Ratio : 0.0389 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0389 |
| March 31, 2026 | 0.0239 |
| December 31, 2025 | 0.0521 |
| September 30, 2025 | 0.0313 |
| June 30, 2025 | 0.0385 |
| March 31, 2025 | 0.0337 |
| December 31, 2024 | 0.0298 |
| September 30, 2024 | 0.027 |
| June 30, 2024 | 0.0265 |
| March 31, 2024 | 0.0232 |
| December 31, 2023 | 0.0679 |
| September 30, 2023 | 0.0581 |
| June 30, 2023 | 0.0508 |
| March 31, 2023 | 0.0494 |
| December 31, 2022 | 0.0488 |
| September 30, 2022 | 0.0469 |
| June 30, 2022 | 0.1142 |
| March 31, 2022 | 0.1026 |
| December 31, 2021 | 0.0932 |
| September 30, 2021 | 0.0852 |
| June 30, 2021 | 0.0928 |
| March 31, 2021 | 0.0812 |
| December 31, 2020 | 0.0727 |
| September 30, 2020 | 0.0649 |
| June 30, 2020 | 0.0609 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.4094 |
| December 31, 2019 | -0.1398 |
| September 30, 2019 | 0.4066 |
| June 30, 2019 | 0.3628 |
| March 31, 2019 | 0.2634 |
| December 31, 2018 | 0.2213 |
| September 30, 2018 | 0.197 |
| June 30, 2018 | 0.3906 |
| March 31, 2018 | 0.3102 |
| December 31, 2017 | 0.2557 |
| September 30, 2017 | 0.0142 |
| June 30, 2017 | 0.0207 |
| March 31, 2017 | 0.0256 |
| December 31, 2016 | 0.0295 |
| September 30, 2016 | 0.0332 |
| June 30, 2016 | 0.0354 |
| March 31, 2016 | 0.037 |
| December 31, 2015 | 0.0378 |
| September 30, 2015 | 0.0371 |
| June 30, 2015 | 0.0372 |
| March 31, 2015 | 0.0343 |
| December 31, 2014 | 0.0724 |
| September 30, 2014 | 0.0675 |
| June 30, 2014 | 0.0594 |
| March 31, 2014 | 0.235 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| SELLAS Life Sciences Group, Inc. | 0.0054 |
| Marker Therapeutics, Inc. | 0.00 |
| Rezolute, Inc. | 0.0095 |
| Krystal Biotech, Inc. | 0.0065 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 165.30M |
| Total Liabilities (Quarterly) | 37.92M |
| Shareholders Equity (Quarterly) | 127.38M |
| Current Ratio | 4.703 |
| Net Debt Paydown Yield | -0.01% |